Business Context and Reporting Period
Company: BiondVax Pharmaceuticals Ltd. (Note: Metadata listed "Scinai Immunotherapeutics," but the filing text identifies the registrant as BiondVax Pharmaceuticals Ltd.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Quarter and Six Months ended June 30, 2015
Filing Date: August 24, 2015
Business Overview: BiondVax is an innovative biopharmaceutical company developing M-001, a universal flu vaccine designed to provide multi-season and multi-strain protection against influenza. The company targets three indications: a standalone universal vaccine, a seasonal primer for the elderly, and a pre-pandemic primer.
Key Financial Metrics
All figures in thousands of NIS (New Israeli Shekels) unless otherwise noted. USD conversions provided in the filing are based on an exchange rate of 1 USD = 3.769 NIS.
| Metric | Six Months Ended June 30, 2015 | Six Months Ended June 30, 2014 |
|---|---|---|
| Revenue | 811 (Grant revenues from OCS and EU) | 100 |
| Operating Loss | (5,035) | (4,202) |
| Net Loss | (7,066) | (4,190) |
| Net Cash Used in Operating Activities | (4,708) | (3,447) |
| Net Cash Provided by Financing Activities | 33,753 | - |
| Cash and Cash Equivalents (Ending Balance) | 37,955 | 14,187 |
| Total Assets | 45,422 | 21,665 |
| Shareholders' Equity | 35,935 | 20,036 |
Debt and Liquidity: The company has no traditional debt. Long-term liabilities of 8,024 NIS are primarily attributable to severance compensation reserves and warrants issued during the IPO. Liquidity improved significantly due to the IPO, with cash balances rising from 14,187 NIS to 37,955 NIS.
Material Changes vs. Prior Period
- Capital Raise: The most significant change was the completion of a U.S. Initial Public Offering (IPO) on May 15, 2015. The company sold 1,910,000 ADSs and warrants, raising gross proceeds of approximately $10.12 million (approx. 36,607 NIS). This resulted in a substantial increase in cash and shareholders' equity.
- Operating Expenses: Research and Development (R&D) expenses increased to 3,785 NIS (from 3,075 NIS in the prior six months), driven by BVX-006 clinical trial expenses. Marketing, general, and administrative expenses rose to 1,250 NIS (from 1,127 NIS) due to increased business development costs.
- Financial Expenses: Net finance expenses surged to 2,031 NIS (from a net income of 12 NIS in the prior period). This increase is primarily due to the fair value adjustment of warrants issued in the IPO (1,127 NIS) and exchange rate differences.
- Revenue Recognition: Revenue increased to 811 NIS, largely due to grants from the Office of the Chief Scientist (OCS) and the European Union, compared to 100 NIS in the prior period.
Guidance, Outlook, and Risks
Outlook and Capital Needs: Management anticipates that current financial resources, bolstered by the May 2015 IPO, will suffice to fund business plans for at least 20 months. However, the company expects to require substantial additional financing to achieve its long-term business strategy.
Regulatory and Clinical Milestones:
- FDA Approval: Received FDA approval for an Investigational Drug Application (IND) on June 17, 2015, allowing Phase 2 trials for M-001 to proceed.
- Clinical Results: Announced preliminary positive results for the BVX-006 trial (June 29, 2015) indicating safety and efficacy. Also announced statistical analysis of the BVX-005 trial (August 3, 2015) showing increased immunogenicity against new H3N2 strains.
Risks and Contingencies:
- Market Risk: Significant exposure to fluctuations in the U.S. Dollar and Euro. The company holds dollar cash balances for U.S. clinical trials and plans to convert approximately $4 million of NIS to USD.
- Seasonality: While M-001 is designed for multi-year protection, sales of the "seasonal primer" indication are expected to be seasonal (September-November).
- Regulatory: Success depends on obtaining regulatory approvals for the three intended indications.
Management Commentary: The Board approved significant compensation updates, including salary increases for the CEO and Chief Scientific Officer, and the grant of unregistered options to officers and employees.
Investor Verification Checklist
- IPO Proceeds Utilization: Verify the actual burn rate against the projected 20-month runway following the $10.12 million gross raise.
- Warrant Liability: Monitor the fair value of the 1,910,000 public warrants and 95,500 representative warrants, as fluctuations in stock price will impact financial expenses.
- Clinical Trial Progress: Confirm the timeline and enrollment status of the Phase 2 trials authorized by the FDA in June 2015.
- Grant Dependency: Assess the sustainability of revenue streams, noting that current revenue is heavily reliant on government and EU grants (OCS/EU) rather than product sales.
- FX Exposure: Review the company's hedging strategy regarding the conversion of NIS to USD for U.S. operations, given the significant currency exposure.